SomaLogic, Inc. announced that preliminary, unaudited revenue for the full year 2022 is expected to be at the high end of its guidance range of $93 to $98 million, reflecting approximately 20% year-over-year revenue growth.
Standard BioTools Inc.
Equities
SLGC
US83444K1051
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+25.08% | 46.56B | |
+45.49% | 41.67B | |
-0.41% | 41.16B | |
+34.02% | 32.4B | |
+20.73% | 28.18B | |
-6.35% | 28.1B | |
+49.25% | 14.52B | |
+47.88% | 13.74B | |
+1.77% | 12.17B |